Tevimbra® (tislelizumab-jsgr) – New indication
March 5, 2025 - BeiGene announced the FDA approval of Tevimbra (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥ 1).
Top